Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” Talk at Immunology Symposium at the University of Alberta
September 09, 2024 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine New data show improved tolerability in...
Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients
September 09, 2024 07:00 ET
|
Autonomix Medical, Inc.
Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded with a mean 6.67 or 83% reduction...
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
September 09, 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO presents clinical trial progress update at EASD conference
Roivant Provides Update on Graves’ Disease Development Program
September 09, 2024 07:00 ET
|
Roivant Sciences
High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on ATDs...
Nova Vision Acquisition Corp. Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination to October 10, 2024
September 09, 2024 07:00 ET
|
Nova Vision Acquisition Corp.
Singapore, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Nova Vision Acquisition Corp. (NASDAQ: NOVV, the “Company”), a special purpose acquisition company, announced today that Nova Pulsar Holdings Limited,...
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
September 09, 2024 07:00 ET
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms
September 09, 2024 07:00 ET
|
Tilray Brands, Inc.
LISBON, Portugal, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the...
Tilray Medical participe à une étude scientifique sur la fibromyalgie avec des résultats positifs : efficacité du traitement aux cannabinoïdes de la douleur et d’autres symptômes associés à la fibromyalgie
September 09, 2024 07:00 ET
|
Tilray Brands, Inc.
LISBONNE, Portugal, 09 sept. 2024 (GLOBE NEWSWIRE) -- Tilray Medical, division de Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY) et leader mondial du cannabis thérapeutique, qui...
Canoo Expands Presence in Oklahoma and Texas with Engineering Talent and Headquarters Relocation
September 09, 2024 07:00 ET
|
Canoo, Inc.
Canoo Expands Presence in Oklahoma and Texas with Engineering Talent and Headquarters Relocation
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
September 09, 2024 07:00 ET
|
Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...